Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914613 · ClinicalTrials.gov registry record · Phase 1
Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
A Phase 1 study of Diabetic Macular Edema, sponsored by OcuTerra Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 6
- Study locations
NCT02914613: Completed Phase 1 study of Diabetic Macular Edema, sponsored by OcuTerra Therapeutics.
NCT02914613 is a Phase 1 study of Diabetic Macular Edema that has completed, run by OcuTerra Therapeutics. The registered enrollment target is 44 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02914613, a Phase 1 study of Diabetic Macular Edema, has completed, sponsored by OcuTerra Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Diabetic Macular Edema (DME).
Primary Outcome
Percentage of subjects with red blood cell counts in the anterior chamber in the ranges from 0 to \> 30 with the higher number being worse
Conditions Studied
Interventions
- DRUG SF0166 Topical Ophthalmic Solution
Study Locations (6)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- United Medical Research Institute - Inglewood
- Martel Eye Medical Group - Rancho Cordova
Florida
- Center for Retina and Macular Disease - Winter Haven
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Texas
- Retina Consultants of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-08-24 |
| Est. Completion | 2017-05-16 |
| Phase | Phase 1 |
What the finished NCT02914613 record still lists
NCT02914613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which SF0166 Topical Ophthalmic Solution is the first listed.
NCT02914613 lists 6 locations in 4 states (California, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT02914613 about?
NCT02914613 is a clinical study titled "Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)". The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Diabetic Macular Edema (DME).
What is the current status of trial NCT02914613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-08-24. Estimated completion is 2017-05-16.
What conditions does trial NCT02914613 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT02914613?
The interventions under investigation include: SF0166 Topical Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02914613?
This trial is sponsored by OcuTerra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914613 being conducted?
This trial has 6 study locations across California, Florida, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02914613's enrollment target sits among peer trials
44 39th of 63 higher than 25 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI